Anixa Biosciences (NASDAQ:ANIX) Posts Quarterly Earnings Results, Beats Estimates By $0.01 EPS

Anixa Biosciences (NASDAQ:ANIXGet Free Report) issued its earnings results on Tuesday. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.01, Zacks reports.

Anixa Biosciences Stock Down 5.6 %

ANIX opened at $2.36 on Friday. The firm has a 50 day moving average price of $2.93 and a 200-day moving average price of $3.54. Anixa Biosciences has a twelve month low of $2.21 and a twelve month high of $5.13. The stock has a market capitalization of $75.54 million, a price-to-earnings ratio of -6.38 and a beta of 0.84.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and set a $12.00 price objective on shares of Anixa Biosciences in a report on Thursday, March 21st.

Get Our Latest Stock Analysis on ANIX

Insider Activity

In related news, Director Arnold M. Baskies acquired 10,000 shares of the firm’s stock in a transaction dated Friday, March 15th. The stock was purchased at an average cost of $3.63 per share, with a total value of $36,300.00. Following the completion of the acquisition, the director now directly owns 110,000 shares of the company’s stock, valued at $399,300. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Anixa Biosciences news, Director Lewis H. Titterton, Jr. bought 15,009 shares of Anixa Biosciences stock in a transaction on Tuesday, April 9th. The stock was acquired at an average cost of $3.28 per share, with a total value of $49,229.52. Following the completion of the acquisition, the director now owns 838,037 shares in the company, valued at $2,748,761.36. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Arnold M. Baskies bought 10,000 shares of Anixa Biosciences stock in a transaction on Friday, March 15th. The shares were acquired at an average cost of $3.63 per share, with a total value of $36,300.00. Following the completion of the acquisition, the director now owns 110,000 shares of the company’s stock, valued at approximately $399,300. The disclosure for this purchase can be found here. Insiders purchased 55,009 shares of company stock valued at $182,130 over the last three months. Insiders own 22.60% of the company’s stock.

Anixa Biosciences Company Profile

(Get Free Report)

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.

See Also

Earnings History for Anixa Biosciences (NASDAQ:ANIX)

Receive News & Ratings for Anixa Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anixa Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.